Guggenheim Capital LLC Sells 82,768 Shares of Royalty Pharma plc (NASDAQ:RPRX)

Guggenheim Capital LLC lessened its stake in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 53.1% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 73,081 shares of the biopharmaceutical company's stock after selling 82,768 shares during the period. Guggenheim Capital LLC's holdings in Royalty Pharma were worth $1,864,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Brooklyn Investment Group increased its stake in Royalty Pharma by 1,006.9% in the 4th quarter. Brooklyn Investment Group now owns 963 shares of the biopharmaceutical company's stock worth $25,000 after buying an additional 876 shares in the last quarter. Allworth Financial LP boosted its stake in shares of Royalty Pharma by 417.6% in the fourth quarter. Allworth Financial LP now owns 1,087 shares of the biopharmaceutical company's stock worth $28,000 after acquiring an additional 877 shares during the period. Riverview Trust Co grew its position in shares of Royalty Pharma by 3,953.3% during the fourth quarter. Riverview Trust Co now owns 1,216 shares of the biopharmaceutical company's stock worth $31,000 after purchasing an additional 1,186 shares in the last quarter. Fifth Third Bancorp raised its stake in Royalty Pharma by 187.1% during the 4th quarter. Fifth Third Bancorp now owns 1,530 shares of the biopharmaceutical company's stock valued at $39,000 after purchasing an additional 997 shares during the period. Finally, Rakuten Securities Inc. raised its stake in Royalty Pharma by 160.5% during the 4th quarter. Rakuten Securities Inc. now owns 1,628 shares of the biopharmaceutical company's stock valued at $42,000 after purchasing an additional 1,003 shares during the period. Hedge funds and other institutional investors own 54.35% of the company's stock.

Royalty Pharma Price Performance

NASDAQ:RPRX traded down $0.50 during trading hours on Wednesday, reaching $31.69. The stock had a trading volume of 4,185,299 shares, compared to its average volume of 3,257,363. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.44 and a current ratio of 1.44. The stock has a market capitalization of $18.27 billion, a PE ratio of 21.86, a PEG ratio of 2.31 and a beta of 0.50. Royalty Pharma plc has a 52 week low of $24.05 and a 52 week high of $34.20. The company has a 50 day moving average price of $32.56 and a two-hundred day moving average price of $29.34.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last announced its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.15 earnings per share for the quarter, topping the consensus estimate of $0.99 by $0.16. Royalty Pharma had a net margin of 37.94% and a return on equity of 24.40%. As a group, sell-side analysts anticipate that Royalty Pharma plc will post 4.49 earnings per share for the current fiscal year.

Royalty Pharma Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Friday, May 16th will be given a $0.22 dividend. The ex-dividend date of this dividend is Friday, May 16th. This represents a $0.88 annualized dividend and a yield of 2.78%. Royalty Pharma's dividend payout ratio is currently 60.69%.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on RPRX shares. Citigroup reaffirmed a "buy" rating on shares of Royalty Pharma in a report on Friday, March 28th. TD Cowen raised shares of Royalty Pharma to a "strong-buy" rating in a research note on Tuesday, December 24th. One investment analyst has rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Buy" and an average price target of $42.50.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.